Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
A Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Sponsor: Medical College of Wisconsin
Terminated
No longer have funding support to complete the pharmacogenetics component.
Other terminated trials from Medical College of Wisconsin
Other Acute Myeloid Leukemia trials with similar outcome
A PHASE2 clinical study on Acute Myeloid Leukemia and Myelodysplastic Syndrome, this trial is terminated or withdrawn. The trial is conducted by Medical College of Wisconsin and has accumulated 14 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Apr 2025 — Present [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2023 — May 2024 [monthly]
Recruiting PHASE2
▶ Show 9 earlier versions
-
May 2022 — May 2023 [monthly]
Recruiting PHASE2
-
May 2021 — May 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2019 — Apr 2020 [monthly]
Recruiting PHASE2
-
Aug 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Medical College of Wisconsin
For direct contact, visit the study record on ClinicalTrials.gov .